ModifiedBlue Cross Blue Shield - New MexicoPolicy CPCPLAB019

Thyroid Disease Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - New Mexico Policy CPCPLAB019 alerts

Get alerted when Policy CPCPLAB019 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines reimbursement and clinical criteria for laboratory testing of thyroid function and related antibodies for Blue Cross Blue Shield - New Mexico members; applies to providers submitting claims for thyroid-related lab services under BCBSNM plans.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLAB019

Change TypeMaterial updates to indications, monitoring intervals, and coding

Effective DateAug 8, 2025

Last ReviewApr 28, 2025

Next Review DateN/A

Key ActionDocument clinical indication (e.g., ≥2 pregnancy losses, thyroid nodule, or other specified criteria) when submitting claims to support reimbursable thyroid testing.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedBlue Cross Blue Shield - New MexicoPolicy CPCPLAB019

Thyroid Disease Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - New Mexico Policy CPCPLAB019 alerts

Get alerted when Policy CPCPLAB019 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLAB019

Change TypeMaterial updates to indications, monitoring intervals, and coding

Effective DateAug 8, 2025

Last ReviewApr 28, 2025

Next Review DateN/A

Key ActionDocument clinical indication (e.g., ≥2 pregnancy losses, thyroid nodule, or other specified criteria) when submitting claims to support reimbursable thyroid testing.

SourceLink

POLICY UPDATE CHANGES

TSH testing criterion for individuals capable of becoming pregnant updated to require testing for those who have experienced two or more pregnancy losses.

TSH testing for individuals with a thyroid nodule was added as a reimbursable indication.

Reformatted antibody testing guidance: testing once every three years for thyroid antibodies (Tg-Ab, TPOAb, TRAB, TSI) may be reimbursable for individuals with hypothyroidism or hyperthyroidism.

Clarified monitoring for secondary (central) hypothyroidism to include fT4 monitoring every 6 weeks after dose changes and annually when stable.

One-time TSH screening indications were consolidated and enumerated (high-risk asymptomatic individuals, thyroid/neoplasm of endocrine glands, chronic/acute urticaria, pediatric short stature, pediatric failure-to-thrive).

Added CPT/CLIA code 83520 to the coding section.

16procedure codes

multiplemonitoring schedules

severalnon-reimbursable tests

presentpregnancy guidance

3-yearantibody interval

2+pregnancy loss trigger

Coverage Criteria for Thyroid-Related Laboratory Testing

Medically Necessary and Covered Indications

Thyroid function tests may be reimbursable in specific clinical scenarios and per specified monitoring intervals.

Hypothyroidism evaluation and monitoring: Covered when TSH is used to confirm or rule out primary hypothyroidism; free T4 (fT4) as follow-up to abnormal TSH; TSH and fT4 for suspected secondary (central) hypothyroidism; for individuals treated for primary hypothyroidism, monitor with TSH and fT4 every 6 weeks after a dosage change and annually when stable; for individuals treated for secondary hypothyroidism, monitor with fT4 every 6 weeks after a dosage change and annually when stable.

See Note 1 for symptoms list.

Hyperthyroidism evaluation and monitoring: Covered when TSH is used to confirm or rule out overt hyperthyroidism; free T4 (fT4) as follow-up to abnormal TSH; total T3 (TT3) or free T3 (fT3) to confirm hyperthyroidism; fT4 to distinguish overt from subclinical hyperthyroidism; monitoring after treatment with repeat TSH and fT4 every 8 weeks during the first year and annual monitoring thereafter for risk of relapse or late-onset hypothyroidism.

See Note 2 for symptoms list; annual monitoring after first year even if asymptomatic.

Asymptomatic at-risk one-time screening: One-time TSH screening may be reimbursable for asymptomatic individuals at high risk for thyroid disease due to personal or family history of thyroid dysfunction; personal or family history of type 1 diabetes or other autoimmune disease; disease or neoplasm of the thyroid or other endocrine glands; chronic or acute urticaria; pediatric short stature; or pediatric failure-to-thrive.one-time

Consolidated one-time screening criteria.

Pregnancy and postpartum: For pregnant or postpartum individuals with symptoms of thyroid dysfunction, TSH and fT4 testing once every 4 weeks may be reimbursable. For pregnant/postpartum individuals diagnosed with hyperthyroidism, total T4 (TT4), antithyroglobulin antibody (TgAb), thyrotropin receptor antibodies (TRAb), and antithyroid peroxidase antibody (TPOAb) may be reimbursable.frequency: every 4 weeks

Assays must have trimester-specific normal ranges; fT4 preferred; TT4 useful if discordant or trimester-specific fT4 ranges unavailable.

Immune reconstitution therapy monitoring: TSH testing once every 3 months with reflex fT4 and fT3 when TSH is abnormal is reimbursable for individuals undergoing immune reconstitution therapy (e.g., alemtuzumab for MS, HIV on HAART, post-allogeneic BMT/HSCT).every 3 months

Reflex fT4/fT3 when TSH abnormal.

Hypothalamic-pituitary disease monitoring: For individuals with hypothalamic-pituitary disease, monitor TSH and fT4 biannually for individuals less than 18 years of age and annually for individuals 18 years of age or older.biannually (<18), annually (>=18)

Primary mitochondrial disease screening: Annual screening of TSH and fT4 for individuals diagnosed with primary mitochondrial disease may be reimbursable.annually

Thyroid cancer surveillance: Serum thyroglobulin and/or Tg-Ab testing may be reimbursable for detection of tumor recurrence, post-surgical evaluation, surveillance, and maintenance for differentiated thyroid carcinomas.

Periodic antibody testing: For individuals with hypothyroidism or hyperthyroidism, testing once every three years for thyroid antibodies (Tg-Ab, TPOAb, TRAb, thyroid-stimulating immunoglobulins/TSI) may be reimbursable.every 3 years

Specific antibodies enumerated.

Not Medically Necessary / Not Reimbursable

Explicitly not reimbursable tests and scenarios

Not reimbursable tests: Testing for thyrotropin-releasing hormone (TRH) or thyroxine-binding globulin (TBG) for evaluation of cause of thyroid dysfunction is not reimbursable; testing of reverse T3, T3 uptake and total T4 is not reimbursable for situations not otherwise specified as covered; measurement of total T3 (TT3) and/or free T3 (fT3) for assessment of hypothyroidism or to guide levothyroxine dosing is not reimbursable.

Screening in asymptomatic nonpregnant individuals: TSH testing during a general exam without abnormal findings is not reimbursable for asymptomatic nonpregnant individuals.

Reimbursable Indications and Monitoring

Reimbursable testing indications and monitoring intervals (summarized from updated Reimbursement Information):

Pregnancy-related testing: TSH testing is reimbursable for individuals capable of becoming pregnant who have experienced two or more pregnancy losses.>=2 pregnancy losses

Clarified from prior wording; 'undergoing evaluation for infertility' removed.

Thyroid nodule: TSH testing is reimbursable for individuals with a thyroid nodule.one-time or as clinically indicated

Newly added reimbursable indication.

Thyroid antibody monitoring: For individuals with hypothyroidism or hyperthyroidism, testing once every three years for thyroid antibodies (Tg-Ab, TPOAb, TRAb, TSI) may be reimbursable.every 3 years

The policy specifies several thyroid-related assays that are not reimbursable except where explicitly listed as covered. Specifically, testing for thyrotropin-releasing hormone (TRH) or thyroxine‑binding globulin (TBG) to evaluate the cause of thyroid dysfunction is not reimbursable. Similarly, assays including reverse T3, T3 uptake, and total T4 are not reimbursable for indications outside the limited covered scenarios. Measurement of total T3 (TT3) and/or free T3 (fT3) is not reimbursable for the routine assessment of hypothyroidism or to guide levothyroxine dosing. Finally, routine thyroid testing for asymptomatic, nonpregnant individuals during a general examination without abnormal findings is not reimbursable.

The policy update removed the prior phrase referencing individuals who "are undergoing evaluation for infertility" from the pregnancy-related TSH testing criterion. The revised language now limits reimbursable TSH testing to individuals capable of becoming pregnant who have experienced two or more pregnancy losses (see the pregnancy-related criteria).

The document clarifies that total T3 (TT3) and/or free T3 (fT3) are not appropriate for routine assessment of hypothyroidism and are not reimbursable when used to assess levothyroxine dose. TSH (with reflex or follow-up fT4 as indicated) remains the appropriate primary marker for diagnosis and routine monitoring; TT3/fT3 testing should not be used for routine screening in asymptomatic individuals.

Policy history reflects prior language revisions and reorganization described in the update notes; these historical edits (for example, moving secondary hypothyroidism monitoring into the monitoring section and other rewording) are documented in the Policy Update History but are not restated in full within these criteria explanations.

Procedure and Billing Codes

Procedure Codes Listedmixed

80438
80439
83519
83520
84432
84436
84439
84442
84443
84445

1–10 of 16

1/2

Added/Referenced CodesCPT

83520

Thyroid peroxidase (TPO) antibody (document added this code)

Provider Responsibilities and Prior Authorization

Prior Authorization

Prior authorization and product variation — review plan documents

Review applicable plan documents and employer/payer rules before submitting claims for thyroid laboratory testing. The plan has implemented lab management reimbursement criteria and not all requirements apply to every product; coverage, prior authorization, and reimbursement rules can vary by product.

Verify member-specific plan documents (Certificates of Benefits, Summary Plan Description) to determine applicable coverage and prior authorization requirements.
Follow plan-specific lab management rules because not all policy requirements apply to every product.

Prior Authorization

Added coding; check PA for antibody/specialty testing (83520)

Confirm coding and prior authorization requirements for newly added and existing laboratory CPT/CLIA codes, including CPT code 83520 which was added to the policy.

Code 83520 (thyroid peroxidase antibody) was added — verify whether prior authorization is required by the member's payer/employer rules for antibody or specialty testing.

Background and Rationale

Thyroid function testing is used to diagnose and monitor hypothyroidism and hyperthyroidism, and to follow patients who are at increased risk because of medications, pregnancy, immune reconstitution therapy, or underlying thyroid disease. Clinical strategies prioritize TSH as the first-line screening test, with free T4 (fT4) used to follow up abnormal TSH results or to monitor central (secondary) hypothyroidism; selective use of T3 (TT3/fT3) and thyroid antibody testing is reserved for specific clinical indications rather than routine use.

Key Terms and Monitoring Definitions

inv-19: TSH, fT4, TT3/fT3, thyroid antibodies — definitions and typical clinical roles for each assay

TSH (Thyroid Stimulating Hormone)Primary screening test to confirm or rule out primary hypothyroidism and to evaluate for overt hyperthyroidism; appropriate initial marker for many indications.

Free T4 (fT4)Follow-up test for abnormal TSH; used with TSH to evaluate suspected secondary (central) hypothyroidism and to distinguish overt from subclinical hyperthyroidism.

Total T3 (TT3) / Free T3 (fT3)Measured to confirm a diagnosis of hyperthyroidism (TT3 or fT3 may be used when indicated); not reimbursable for assessing levothyroxine dosing in hypothyroidism.

Thyroid antibodies (Tg‑Ab, TPOAb, TRAb, TSI)Used for periodic evaluation in individuals with hypothyroidism or hyperthyroidism and for thyroid cancer surveillance (specified antibodies enumerated); testing may be reimbursable once every three years.

inv-20: One-time TSH screening — definition and enumerated high-risk groups for a single screening TSH

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLAB019

Change TypeMaterial updates to indications, monitoring intervals, and coding

Effective DateAug 8, 2025

Last ReviewApr 28, 2025

Next Review DateN/A

Key ActionDocument clinical indication (e.g., ≥2 pregnancy losses, thyroid nodule, or other specified criteria) when submitting claims to support reimbursable thyroid testing.

SourceLink

On This Page

Specific antibodies enumerated in policy.

Secondary (central) hypothyroidism monitoring: For individuals being treated for secondary hypothyroidism, monitor with fT4 every 6 weeks after a dosage change and annually in stable individuals.6 weeks after dose change; annually if stable

Clarified monitoring metric moved into monitoring section.

One-time TSH screening indications: One-time TSH screening is reimbursable for asymptomatic individuals at high risk: personal or family history of thyroid dysfunction; personal or family history of type 1 diabetes or other autoimmune disease; disease or neoplasm of the thyroid or other endocrine glands; chronic or acute urticaria; pediatric short stature; pediatric failure-to-thrive.one-time

Consolidated from previously dispersed items.

Drug monitoring: For asymptomatic individuals prescribed drugs that can interfere with thyroid function, TSH testing is reimbursable annually, when medication/dosage changes, or if symptoms develop; TSH is the appropriate screening marker unless otherwise indicated.annually / with changes / symptom-triggered

Clarified that TSH is the appropriate marker.

Hypothalamic-pituitary disease monitoring: For individuals with hypothalamic-pituitary disease, monitor TSH and fT4 biannually for individuals less than 18 years and annually for individuals 18 years of age or older.biannual (<18) / annual (>=18)

Reformatted and moved from prior numbering.

Ensure all billed codes from the policy code list are checked against payer prior authorization rules before claim submission.

Note

Align orders with reimbursable indications and monitoring intervals

Providers must ensure testing ordered aligns with the policy's reimbursable indications and intervals; misalignment may affect coverage and reimbursement.

Order TSH, fT4, TT3/fT3, or antibody testing only when documentation supports a reimbursable indication or specified monitoring interval.
Confirm whether the patient's clinical scenario (e.g., pregnancy losses, thyroid nodule, hypothyroidism/hyperthyroidism monitoring) meets the policy criteria before testing.

Prior Authorization

Verify PA and correct test coding before ordering

Check prior authorization requirements and product-specific lab management rules before performing antibody or specialty testing, and confirm that selected test codes are valid and appropriate for the clinical indication.

Verify if the payer requires prior authorization for antibody testing or specialty assays.
Use the policy's listed codes when ordering and ensure code combinations conform to HIPAA-approved code sets and payer rules.

Documentation Required

Submit accurate documentation and additional records upon request

Submit accurate, complete documentation of services performed and be prepared to provide additional supporting documentation upon request to substantiate medical necessity.

Include clinical notes, symptoms, medication changes, pregnancy history, dosing changes, and relevant lab results that support the reimbursable indication.
Respond promptly to requests for additional documentation to avoid claim delays or denials.

Documentation Required

Document specific reimbursable clinical indications

Document the specific clinical indication that supports reimbursement — examples include history of two or more pregnancy losses, presence of a thyroid nodule, diagnosis of hypothyroidism or hyperthyroidism, or qualifying one-time high-risk screening criteria.

For pregnancy-related TSH testing, document that the individual capable of becoming pregnant has experienced two or more pregnancy losses.
For antibody monitoring, document diagnosis of hypothyroidism or hyperthyroidism and the date of prior antibody testing if applicable (three-year interval guidance).
For one-time TSH screening, document the specific high-risk reason (e.g., personal/family history of thyroid disease, type 1 diabetes/autoimmune disease, thyroid neoplasm, chronic/acute urticaria, pediatric short stature, failure-to-thrive).

Documentation Required

Documentation and coding compliance — claims subject to review

Ensure claims are coded correctly and supported by documentation; claims are subject to review against benefit coverage, provider contract language, medical policies, and coding edits and may be denied if coding or documentation is insufficient.

Use valid code combinations from HIPAA-approved code sets and follow industry coding standards (CPT, HCPCS, ICD-10-CM).
Anticipate code edit protocols and coding software logic that may flag mismatches between codes and documented indications.

Denial Risk

Coverage alignment required — order only per updated reimbursable indications

Confirm that ordered testing aligns with the updated reimbursable indications (e.g., pregnancy-related TSH testing only for those with two or more pregnancy losses and antibody testing per the specified three‑year interval) to reduce risk of denial.

Do not rely on prior policy language (such as evaluation for infertility) removed from current criteria — order only when current criteria are met.
For antibody testing, follow the policy's every-three-years guidance for individuals with hypothyroidism or hyperthyroidism.

One-time TSH screening — definitionA single TSH test performed for asymptomatic individuals at high risk for thyroid disease; intended as a one-time screen rather than routine surveillance.

High‑risk groups — personal/family historyIndividuals with a personal or family history of thyroid dysfunction or a personal or family history of type 1 diabetes or other autoimmune disease.

High‑risk groups — endocrine disease/neoplasmIndividuals with disease or neoplasm of the thyroid or other endocrine glands.

High‑risk groups — dermatologic and pediatricIndividuals with chronic or acute urticaria; pediatric individuals with short stature or with clinical findings of failure‑to‑thrive.

inv-21: Secondary (central) hypothyroidism monitoring — monitoring strategy using fT4 every 6 weeks after dose changes and annually when stable

Monitoring strategy — test and intervalFor individuals treated for secondary (central) hypothyroidism, monitor with free T4 (fT4) every 6 weeks after a dosage change and annually once stable.

Role of TSHTSH is not relied upon alone for secondary/central hypothyroidism; fT4 is the appropriate monitoring marker in this setting.

Stability scheduleAfter achieving a stable dose, perform annual fT4 testing to confirm continued euthyroidism.